Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients-Reference-Cited by-同舟云学术

Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients

Published:2013-11-11 Issue:11 Volume:8 Page:e80437
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Gandhi Anita K.,Shi Tao,Li Mingyu,Jungnelius Ulf,Romano Alfredo,Tabernero Josep,Siena Salvatore,Schafer Peter H.,Chopra Rajesh

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference23 articles.

1. Identification of a primary target of thalidomide teratogenicity;T Ito;Science,2010

2. Cereblon is a direct target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide;A Lopez-Girona;Leukemia,2012

3. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide;YX Zhu;Blood,2011

4. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha;LG Corral;J Immunol,1999

5. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs;PH Schafer;J Pharmacol Exp Ther,2003

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy;Trends in Molecular Medicine;2024-08

2. Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer;Biomedicine & Pharmacotherapy;2023-06

3. Prognosis analysis of necroptosis-related genes in colorectal cancer based on bioinformatic analysis;Frontiers in Genetics;2022-08-15

4. New Co-Crystals/Salts of Gallic Acid and Substituted Pyridines: An Effect of Ortho-Substituents on the Formation of an Acid–Pyridine Heterosynthon;Crystals;2022-04-03

5. Prognostic Significance of Systemic Inflammation Indices by KRAS Status in Patients with Metastatic Colorectal Cancer;Diseases of the Colon & Rectum;2022-02-21